In recent months, CMI began redirecting many of its efforts to better understand how the human microbiome is involved in the development and severity of COVID-19.
Researchers have since been evaluating samples from patients worldwide to find biological and epidemiological discoveries about the SARS-CoV-2 virus.
CMI director Rob Knight also noted the importance of a reliable HPC technology solution as the Center steps up its groundbreaking efforts to study the RNA microbiome, which is especially relevant because COVID-19 is an RNA virus.
CMI has been working with Panasas since 2015, when they were looking to create an HPC storage infrastructure that could deliver consistently high performance, speed data exploration and discovery, and simplify storage management for administrators.
The CMI team appreciates technology solutions that don't distract researchers from the scientific problems they aspire to solve. By freeing researchers from worries about storage, CMI can accelerate the adoption of advanced scientific technologies.
ActiveStor is a turnkey HPC storage appliance that runs the PanFS parallel file system to accelerate performance at every stage of the computational research process.
It delivers unlimited performance scaling and features a balanced node architecture that prevents hot spots and bottlenecks by automatically adapting to dynamically changing workloads and increasing demands - all at the industry's lowest total cost of ownership.
Panasas delivers high-performance computing data storage solutions that support industry and research innovation around the world.
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Kiora Pharmaceuticals joins Global Genes' RARE-X Vision Consortium
Pilatus Biosciences to present new preclinical data on PLT012 at SITC 2025
Rovia Clinical Research opens new clinical research site in Hattiesburg, Mississippi
ChemDiv extends CMC services collaboration supporting clinical development of ratutrelvir
NeuroKaire and Compass Pathways partner to advance AI-driven research in psychedelic psychiatry
BioArctic reports third-quarter royalties from Leqembi sales
GenSight Biologics secures FDA authorisation for expanded access to GS010/LUMEVOQ in the US
AnHorn Medicines reports positive results from US Phase I trial of AH-001
Curasight advances Phase 2 prostate cancer trial with Curium partnership
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Hemogenyx Pharmaceuticals advances HG-CT-1 trial and opens paediatric recruitment
Rx to Go receives ACHC re-accreditation for pharmacy services